LY2857785

Item number	Size	Delivery time	Price
TGM-TQ0060-1mg	1 mg	7 - 10 business days*	48.00€
TGM-TQ0060-2mg	2 mg	7 - 10 business days*	67.00€
TGM-TQ0060-5mg	5 mg	7 - 10 business days*	112.00€
TGM-TQ0060-1mL	1 ml	7 - 10 business days*	125.00€
TGM-TQ0060-10mg	10 mg	7 - 10 business days*	181.00€
TGM-TQ0060-25mg	25 mg	7 - 10 business days*	371.00€
TGM-TQ0060-50mg	50 mg	7 - 10 business days*	596.00€
TGM-TQ0060-100mg	100 mg	7 - 10 business days*	959.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

Description: LY2857785 is a type I competitive and reversible ATP kinase inhibitor against... more

Close menu

Product information "LY2857785"

Description: LY2857785 is a type I competitive and reversible ATP kinase inhibitor against CDK7/CDK8/CDK9 (IC50s: 246 nM/16 nM/11 nM). Target: CDK, Apoptosis. Smiles: CC(C)c1n(C)nc2ccc(cc12)-c1ccnc(N[C@H]2CC[C@@H](CC2)NC2CCOCC2)n1. References: Yin T, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014 Jun,13(6):1442-56. Mol Cancer Ther. 2014 Jun,13(6):1442-56.

Supplier:	TargetMol
Supplier-Nr:	TQ0060

Properties

Application:	Cdk9 inhibitor
MW:	448.6 D
Formula:	C26H36N6O

Database Information

CAS :	1619903-54-6\| Matching products
KEGG ID :	K02211 \| Matching products

Handling & Safety

Storage:	-20°C
Shipping:	+4°C (International: +4°C)

Caution
Our products are for laboratory research use only: Not for administration to humans!

Information about the product reference will follow. more

Close menu

You will get a certificate here

Go back

Read, write and discuss reviews... more

Close menu

Customer review for "LY2857785"

Write a review